Overview

Fully integrated french CDMO

Skyepharma is a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.

Since 1996, we help our clients to offer the best drug for the benefit of the patient.

In 2016, Skyepharma became the oral business Unit  of the Vectura Group of Companies (www.vectura.com) and transformed into a fully integrated french CDMO [see our History].

In June 2021, Skyepharma becomes a newly independent CDMO looking to further growth.

  • 1996 : Creation of Skyepharma
  • 30 years of experience in oral solid dosage forms
  • More than 110 employees including 1/4 in development department
  • Located near Lyon, FRANCE
  • Fully integrated CDMO since 2016
  • Pharmaceutical Industry
  • Food supplement Industry
  • Development, Manufacturing and Packaging of classic & complex oral solid forms
  • EU GMP certified facilities
  • FDA approved since 1998. Last inspection in september 2019
  • ANVISA approved since 2013
  • Registered at Korean MFDS
  • Products commercialized in US, EU, Brazil and Asia
  • 40% of products exported to the US market
  • March 2019 : 1st batch serialized and aggregated for US market

40

Millions blisters per year

10

Millions Bottles per year

150

Millions capsules per year

2

billions tablets per year

As a CDMO specialized in oral solid forms, our mission is to provide product developmentmanufacturing and packaging services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships.

Our vision is Solving healthcare industry complexity.

Expert and agile french CDMO

 

Skyepharma is deeply committed to performance management and value creation for its clients. Our services are continuously improved to offer state-of-the-art global development, manufacturing and packaging services.

Our partners can rely on our agility and scientific expertise resulting in accelerated time to market and maximized value across all pharmaceutical lifecycle stages.

Fully integrated CDMO

 

Skyepharma fully integrated french CDMO

Our key differentiators

Know how” and Expertise : Controlled release technologies since 1992 as well as a real strong Development expertise. (CDMO with a real D)

Quality and Regulatory : EMA-FDA approved development and manufacturing facility / Experience in US and EU regulatory.

We use lean management practices such as visual management, 5S and 8D programmes.

Agility across all pharmaceutical lifecycle stages.

Team culture : Team is number 1